According to Zacks, “Accelerate Diagnostics, Inc. is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel(TM) system, a rapid diagnostic platform for diagnosis in life-threatening bacterial infections and OptiChem(R) surface coatings for use in micro arraying components. Accelerate Diagnostics Inc., formerly known as Accelr8 Technology Corp., is based in Denver, Colorado. “
AXDX has been the subject of several other research reports. BTIG Research raised Accelerate Diagnostics from a neutral rating to a buy rating in a report on Thursday, August 25th. JPMorgan Chase & Co. increased their price objective on Accelerate Diagnostics from $17.00 to $25.00 and gave the company an overweight rating in a report on Tuesday, August 9th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $25.33.
Shares of Accelerate Diagnostics (NASDAQ:AXDX) opened at 26.73 on Monday. The firm’s 50-day moving average is $23.21 and its 200-day moving average is $16.70. The firm’s market cap is $1.37 billion. Accelerate Diagnostics has a 1-year low of $10.29 and a 1-year high of $28.50.
In other Accelerate Diagnostics news, Director Jack W. Schuler purchased 90,147 shares of the company’s stock in a transaction that occurred on Thursday, June 30th. The shares were acquired at an average price of $13.95 per share, for a total transaction of $1,257,550.65. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 51.40% of the stock is owned by corporate insiders.
A number of large investors have recently bought and sold shares of AXDX. BlackRock Group LTD boosted its stake in Accelerate Diagnostics by 58.0% in the first quarter. BlackRock Group LTD now owns 11,022 shares of the company’s stock worth $159,000 after buying an additional 4,047 shares during the period. HighTower Advisors LLC acquired a new stake in Accelerate Diagnostics during the second quarter worth $188,000. American International Group Inc. boosted its stake in Accelerate Diagnostics by 5.3% in the second quarter. American International Group Inc. now owns 13,263 shares of the company’s stock worth $191,000 after buying an additional 663 shares during the period. State Board of Administration of Florida Retirement System boosted its stake in Accelerate Diagnostics by 11.0% in the second quarter. State Board of Administration of Florida Retirement System now owns 15,898 shares of the company’s stock worth $229,000 after buying an additional 1,580 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in Accelerate Diagnostics by 25,550.8% in the second quarter. JPMorgan Chase & Co. now owns 16,673 shares of the company’s stock worth $240,000 after buying an additional 16,608 shares during the period. Institutional investors and hedge funds own 35.62% of the company’s stock.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.